Bortezomib Improves Survival in Children with Newly Diagnosed T-Cell Lymphoblastic Lymphoma

Adding the proteasome inhibitor bortezomib to chemotherapy significantly improved overall survival in children and young adults with newly diagnosed T-cell lymphoblastic lymphoma (T-LL).

Read more: https://www.newswise.com/articles/chop-led-study-finds-bortezomib-improves-survival-in-children-with-newly-diagnosed-t-cell-lymphoblastic-lymphoma